SCHEMBL24028152

SCHEMBL24028152

COC(=O)c1cccc(NC(=O)/C(=N/O)C(C)=O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.57
ALDH1A1 P00352 2/20 0.56
NPC1 O15118 5/20 0.55
MAPT P10636 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
TP53 P04637 1/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
HPGD P15428 1/20 0.49
GPR17 Q13304 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
ABL1 P00519 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30255908 1.00 RAB9A (0.57) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL25229261 1.00 RAB9A (0.57) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL24028042 0.83 TDP1 (0.49) RAB9AALDH1A1NPC1SMN1; SMN2MEN1
SCHEMBL24028109 0.82 TDP1 (0.48) RAB9AALDH1A1NPC1MAPTMEN1
SCHEMBL24028205 0.81 ACHE (0.47) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL30213119 0.80 RAB9A (0.55) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL2833648 0.80 ALDH1A1 (0.66) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL24028050 0.80 RAB9A (0.55) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL2834454 0.79 RAB9A (0.67) RAB9AALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL12299534 0.79 RAB9A (0.51) RAB9AALDH1A1NPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
CN-115697974-A Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2023-02-03 CN disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 RAB9A 3098/4885ALDH1A1 210/4885NPC1 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.